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Antimicrobials are used to control respiratory disorders during the ovine rearing 28 
period. There is an urgent need to optimize the use of different antimicrobial families 29 
in livestock to tackle the general problem of antimicrobial resistance. The first step to 30 
addressing this problem is gaining insight into the antimicrobial susceptibility 31 
(pharmacodynamic) parameters of ovine pathogens. In this study, the key 32 
pharmacodynamic parameter (MIC) was determined for Pasteurella multocida and 33 
Mannhaemaia haemolytica isolated from ovine respiratory clinical cases using 34 
accepted laboratory methods for bacterial isolation, identification and MIC 35 
determination. In the case of Pasteurella multocida, for 36 
sulfamethoxazole/trimethoprim, MICrange, MIC50 and MIC90 values were 0.004–32 37 
g/mL, 0.063 g/mL and 1 g/mL; for tetracycline 0.016-256 g/mL, 1 g/mL, and 32 38 
g/mL; for enrofloxacin 0.002–32 g/mL, 0.016 g/mL and 0.5 g/mL; for doxycycline 39 
0.063–32 g/mL, 1 g/mL and 16 g/mL. In the case of Mannhaemia haemolytica for 40 
sulfamethoxazole/trimethoprim, MICrange, MIC50 and MIC90 values were 0.004–1024 41 
g/mL, 0.063 g/mL and 1 g/mL; for tetracycline 0.063-256 g/mL, 8 g/mL, and 64 42 
g/mL; for enrofloxacin 0.004–32 g/mL, 0.032 g/mL and 16 g/mL; for doxycycline 43 
0.063–256 g/mL, 2 g/mL L and 16 g/mL. The antimicrobial pattern showed good 44 
susceptibility for ovine respiratory pathogens to various licensed antibiotics including 45 
fluoroquinolones and sulfonamides. However, the antimicrobial susceptibility of 46 
antibiotics in the tetracycline family was variable. Doxycycline showed a better 47 
antimicrobial pattern than tetracycline. Finally, antimicrobial susceptibility monitoring 48 
programs are recommended to provide evidence-based guidance for antimicrobial 49 
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 52 
Introduction 53 
In Spain and Portugal, the production of lambs is based on small ewe production 54 
farms. However, the market of fattening animals needs lambs from many farms to 55 
achieve a minimum size in feedlots (Gonzalez et al, 2016), such that these facilities 56 
have sufficient volume to satisfy meat distribution channels. This industry 57 
organization has advantages in terms of achieving market goals but has serious 58 
drawbacks in terms of disease management because mixing animals of different 59 
origins is a well-known risk factor for disease outbreak in many veterinary species 60 
(Thursfield, 2018). 61 
 62 
Respiratory disease remains one of the most challenging problems in intensive ovine 63 
production systems. The term ovine respiratory disease complex (ORDC) describes 64 
a polymicrobial syndrome that results from a combination of infectious agents, 65 
environmental stressors, population size, management strategies, age, and genetics. 66 
This syndrome causes reduced performance, and an increase in mortality rates and 67 
production costs in the ovine fattening industry worldwide (Black et al, 1997; Luzon 68 
and de las Heras, 1999; Gonzalez et al, 2001; Vilallonga 2013). The aetiology of the 69 
ORDC has been in continuous progression due to pathogen evolution as well as in 70 
management and stressor changes in ovine feedlots (Gonzalez et al, 2016). This 71 
ORDC is the consequence of impairment of the normal respiratory immune system 72 
due to pathogens that are able to damage these defences and establish infection on 73 




complex. In any case, Mannheimia haemolytica (MH), Pasteurella multocida (PM), 75 
Mycoplasma ovipneumoniae and Biberstenia threalosi are the most common 76 
etiologic agents involved (Gonzalez 2015) but viruses like Parainfluenza 3, 77 
Pestivirus, Adenovirus 6 and Syncytial Respiratory Virus could predispose an animal 78 
to bacterial colonization in some cases (Brodgen et al, 1998; Martin and Cid, 2013; 79 
Gonzalez et al, 2016).  On the other hand, many non-infectious predisposing factors 80 
are involved in the ORDC, such as poor environmental conditions (e.g., deficient 81 
ventilation), density, stressors (weaning, feeding changes, transport and social 82 
stress), subacute acidosis, season of the year (summer in Spain and Portugal) and 83 
oxidative stress (pulmonary hypertension and damage to epithelia). Finally, 84 
coccidiosis could be one of the most important trigger factors (Gonzalez et al, 2016) 85 
mainly during the first week at the feedlot.  86 
The clinical manifestation of affected lambs can be septicemic, acute, subacute, 87 
chronic and subclinical (Gomez and Garijo, 2013; Gonzalez 2015). Although ORDC 88 
is the most important cause of mortality in lambs older than 42 days of age (Lacasta 89 
et al, 2008), clinical signs of the syndrome may not be as evident highlighting the 90 
importance of the chronic or subclinical form. Thus, close to 33% of lambs raised in 91 
current feedlots have some degree of lesions in their lungs at the slaughterhouse 92 
(Gonzalez 2015). Moreover, 75% of lambs were asymptomatic and had never been 93 
treated despite presenting some lung lesions at slaughter (Luzon and De las Heras, 94 
1999). 95 
 96 
The diagnosis, prophylaxis and treatment strategies for ovine respiratory disease 97 
complex should be adapted, in a case-by-case situation, depending on the relevance 98 




should be based on applying measures to control diseases in a cost-effective way 100 
such as improving environmental conditions, decreasing density, mitigating stressors 101 
and controlling subacute acidosis and parasitism. Other measures include 102 
vaccinating against the major bacterial diseases and the use of antimicrobials to 103 
control bacterial diseases with a therapeutic or metaphylactic goal. Unfortunately, 104 
there are few registered vaccines and antimicrobials to apply in ovine animals. Thus, 105 
antimicrobials remain an essential tool to control ORDC under field conditions (Martin 106 
and Cid, 2013, Fernandez and Rey, 2013). 107 
 108 
The major issues for practitioners when treating a large population of animals with 109 
antimicrobials are maximizing the likelihood of a favorable clinical outcome and 110 
minimizing the appearance and development of antimicrobial resistance. To optimize 111 
the use of these drugs, it is critical to have updated pharmacokinetic (PK) and 112 
pharmadynamic (PD) data about antimicrobials (Mckellar et al, 2004). Unfortunately, 113 
there is a scarcity of public knowledge about the PK and PD of antimicrobials in ovine 114 
medicine. On the other hand, it has been strongly recommended that program be 115 
developed to monitor the usage of antimicrobial agents and the occurrence of 116 
antimicrobial resistance among food animals at the European level (Aarestrup et al,, 117 
2008; EMA AMEG 2014; EMA AMEG 2019). In Spain, a national antimicrobial 118 
resistance monitoring program has been underway since 2014 (PRAN 2014). The 119 
bacterial species monitored, the antimicrobial agents tested, as well as the 120 
methodology used, are being homogenized to make data comparable between and 121 
across species in Spain (PRAN, 2019). In addition, this program also provides data 122 
on the consumption of antimicrobial agents in all veterinary species. Today, there is 123 




involved in ORDC in Spain and Portugal. Much of the information available is very 125 
old, was obtained by obsolete methodology (Diker et al, 1994) or comes from a 126 
geographical area unrelated to the European context (Marru et al, 2013).  127 
The main objective of this work was to obtain pharmacodynamic information about 128 
Pasteurella multocida and Mannhaemia haemolytica in ovine animals following a 129 
methodology recommended by a national antimicrobial resistance control program in 130 
Spain. This information is necessary to obtain updated information to optimize the 131 
use of antimicrobials for this species following the general recommendations about 132 
prudent use of antimicrobials.  133 
 134 
Material and methods 135 
Animals and sampling 136 
One-hundred twenty-eight respiratory clinical cases from 60 ovine feedlots were 137 
studied between February of 2015 and March of 2019 in Spain and Portugal. In these 138 
cases, a percentage of the feedlot showed respiratory symptoms (cough, fever, 139 
depression and dyspnoea) and the mortality rate significantly increased versus the 140 
baseline situation during the respiratory outbreak due mainly to respiratory causes. It 141 
was not sampled any animal that was treated with antimicrobials prior to sample 142 
collection. In each clinical case, a minimum and maximum number of 3 and 5 143 
animals, with overt respiratory symptoms, were sampled, respectively. These animals 144 
were randomly selected if more than 5 animals showed respiratory symptoms at the 145 
same time. Unfortunately, it was not possible to have information about exact age, 146 
breed and days on feed of the animals because this data is not individually recorded 147 
in ovine fattening farms. Samples were drawn from pneumonic lesions in the lung 148 




showing respiratory symptoms (63 samples). In the case of lung sample collection, a 150 
section of 5x5 cm of lung was collected from a lobule including healthy and 151 
pneumonic tissue. On the other hand, tracheobronchial lavage was carried out using 152 
a previous published method adapted to ovine (Hoffman et al, 2008). Briefly, 30-40 153 
cm of a catheter of 2.7 mm of diameter was inserted through one of the nostrils into 154 
the trachea. Then, 20 cm3 of physiological serum were flushed and immediately 155 
aspirated with the same syringe. Afterwards, between 3 to 10 cm3 of tracheobronchial 156 
lavage were drawn. This sample was stored in a sterile container and sent 157 
immediately to the laboratory. In only one case, a nasal swab (one sample) was also 158 
collected from a sick lamb.  159 
 160 
Bacterial isolation and identification 161 
The surface of the lung was sterilized using surgical material at high temperature. 162 
Afterwards, an incision was performed with a scalpel and a sterile loop was used to 163 
sample inside the lung. In the case of tracheobronchial lavages, samples were 164 
uniformly mixed, and 10 l were streaked on the blood agar plate surface with a 165 
sterile loop. Finally, swab samples were surfaced onto the blood agar. For all the 166 
samples, sterile loops were surfaced onto blood agar (tryptic soy agar containing 5% 167 
sheep red blood cells) (BA) plates (Oxoid PB 5039A) with an incubation at 35–37°C 168 
in aerobic conditions for 24–48 hours. Identification of isolates were carried out by 169 
matrix-assisted laser desorption ionization-time of flight (MALDI-TOF, Bruker 170 
Daltonics, Bremen, Germany). Individual strains were stored at -70°C in skim milk. 171 
For MIC testing, bacteria were thawed and cultured two times on the same agar 172 





Antimicrobial compounds 175 
Trimetropim (batch J1511036) and sulfadiazine (batch  PX1-SD-1510033) were 176 
kindly provided by Laboratorios Jaer SA whereas doxycycline hiclate (batch 177 
YD140201015) was provided by Laboratorios SP Veterinaria. Tetracycline 178 
hydrocloride (batch T8032) and enrofloxacin (batch17849) were purchased 179 
commercially from Sigma Aldrich. All the antimicrobials were reconstituted based on 180 
manufacturer’s recommendations. Fresh stock solutions or those prepared from 181 
frozen samples (-70°C) were used. For quality control, Staphylococcus aureus ATCC 182 
29213  from  American Type Culture Collection (ATCC) control strain was included in 183 
each susceptible assay to ensure performance of the susceptibility assays; MIC 184 
values needed to be within acceptable ranges for each organism/drug. 185 
MIC determination 186 
MIC testing was carried out following the recommended CLSI procedure for ten 187 
strains, five of PM and MH (VET08, 2018) that were randomly chosen between all 188 
the available ones. Briefly, Mueller-Hinton broth (MHB) containing a two-fold 189 
concentration of drug was added to the first column of a 96-well micro-dilution tray 190 
and serially diluted concentrations with MHB solution were prepared (from 0.001 to 191 
1024 g/mL for all the antimicrobials). A 0.5 McFarland density, established with a 192 
calibrated nephelometer (Biosan Medical-Biological Research & Technologies, Riga, 193 
Latvia), of Pasteurella multocida and Mannheimia haemolytica was further diluted to 194 
5 x 105 cfu/ml, added to the microdilution tray containing drug and incubated for 18–195 
24 hours (35–37°C) in aerobic conditions. To ensure the inoculum concentration, the 196 
counting of bacterial colonies per mL (cfu/mL) was carried out by serial dilution over 197 
the surface of a blood agar plate for 10 strains. The MIC was established as the 198 




repeated twice on separate days and the average value was accepted as the final 200 
one. In parallel, MIC for the same Pasteurella multocida and Mannheimia 201 
haemolytica strains were performed by test strip (Epsilon test or E-test) to evaluate 202 
the agreement between the two techniques. For MIC determination by test strip, 203 
tetracycline (TET) (Oxoid Limited, Hampshire, United Kingdom), doxycycline (DOX) 204 
(Liofilchem S.R.L., Roseto degli Abruzzi, Italy), trimethoprim/sulfamethoxazole (SXT) 205 
(Liofilchem S.R.L., Roseto degli Abruzzi, Italy), and enrofloxacin (ENR) (Liofilchem 206 
S.R.L., Roseto degli Abruzzi, Italy) strips were used. It was not feasible to use the E-207 
test with sulfadiazine/trimethoprim because it is not commercially available. The 208 
inoculum was prepared as previously described. Briefly, a 0.5 McFarland density, 209 
established with a nephelometer (Biosan Medical-Biological Research & 210 
Technologies, Riga, Latvia), of  Pasteurella multocida and Mannheimia haemolytica 211 
was spread on a Muller Hinton Agar plate (Oxoid Limited, Hampshire, United 212 
Kingdom) using a sterile cotton swab and the test strip was applied to the agar 213 
surface. After 18 hours of incubation at 37ºC the MIC value was read from the scale 214 
in units of µg/mL where the ellipse edge intersects the side strip. 215 
For the rest of the bacterial strains of PM and MH, minimum Inhibitory 216 
Concentrations (MIC) of SXT, TET, ENR and DOX were determined using the E-Test 217 
technique based on the results obtained using both techniques. 218 
 219 
Data analysis 220 
MIC distributions were determined for each species-antimicrobial combination. The 221 
MIC distributions were used to define MIC50, MIC90, and a tentative epidemiological 222 
breakpoint ECOFF for differentiation between susceptibility and strains with some 223 




of the strains, respectively. ECOFFs were determined from MIC distributions for each 225 
species-drug combination, as recommended by EUCAST (Turnidge et al, 2006), with 226 
susceptible strains being the population with MIC at or below the ECOFF and strains 227 
with some gene of resistance having a MIC of > ECOFF from an epidemiological 228 
point of view.  229 
The agreement between the microdilution and E-test technique to determine MIC 230 
was assessed using the Lin´s concordance correlation coefficient as described by 231 
Watson and Petrie, 2010. 232 
 233 
Results 234 
Pasteurella multocida (n=60) and Mannheimia haemolitica (n=68) were isolated in 235 
most cases, although Biberstenia threalosi and Escherichia coli were found, but only 236 
in a few cases. These latter microorganisms were not included in the study due to the 237 
low number of available strains. As explained in the Material and Methods section, 238 
the MIC value was determined using microdilution and E-test techniques for 10 239 
randomly selected strains whose MIC values were highly variable. The agreement 240 
between the two techniques was perfect (>0.999) for enrofloxacin, and substantial 241 
(between 0.950 and 0.990) for tetracycline and sulfamethoxazole/trimethoprim. In the 242 
case of doxycycline, the agreement between the two techniques was moderate 243 
(0.930). Based on these results (Table 1), the E-test was used to determined the 244 
antimicrobial susceptibility for all the strains included in the study. 245 
 246 
MIC data for PM and MH strains and the four antimicrobials are shown in Table 2. In 247 




and MIC90 values were 0.004–32 g/mL, 0.063 g/mL and 1 g/mL; for tetracycline 249 
0.016-256 g/mL, 1 g/mL, and 32 g/mL; for enrofloxacin 0.002–32 g/mL, 0.016 250 
g/mL and 0.5 g/mL; and for doxycycline 0.063–32 g/mL, 1 g/mL and 16 g/mL. 251 
On the other hand, in the case of Mannhaemia haemolytica for 252 
sulfamethoxazole/trimethoprim, MICrange, MIC50 and MIC90 values were 0.004–1024 253 
g/mL, 0.063 g/mL and 1 g/mL; for tetracycline 0.063-256 g/mL, 8 g/mL, and 64 254 
g/mL; for enrofloxacin 0.004–32 g/mL, 0.032 g/mL and 16 g/mL; and for 255 
doxycycline 0.063–256 g/mL, 2 g/mL L and 16 g/mL. 256 
 257 
The distributions of MIC for SXT, TET, ENR and DOX are shown in Figures 1, 2, 3 258 
and 4, respectively, and tentative ECOFF values are superposed on the figures as a 259 
red line. The distributions of SXT and ENR are clearly unimodal for PM and MH. The 260 
percentage of strains with a MIC value above the ECOFF value at 99% of the 261 
confidence level (Figures 1 and 3) of SXT and ENR were 16.7 and 15% for PM and 262 
25 and 33.8% for MH, respectively. On the other hand, the distributions for TET and 263 
DOX were bimodal for both pathogens. The percentage of strains with a MIC value 264 
above the ECOFF value at 99% of the confidence level of TET and DOX were 40 265 










Table 1. Lin´s concordance correlation coefficient between the MIC value obtained 273 








MIC TET MIC ENR MIC DOX 
E-test SXT 0.980 NA NA NA 
E-test TET NA 0.980 NA NA 
E-test ENR NA NA 0.999 NA 
E-test DOX NA NA NA 0.930 
NA: Non-applicable 276 
 277 
Table 2 MIC50, MIC90 and tentative epidemiological breakpoint (ECOFF) with a 278 
confidence level of 99% for Pasteurella multocida (n=60 strains) and Mannhaemia 279 
haemolytica (n=68 strains) isolated from lung or tracheobronchial lavage of lambs 280 























































































































The choice of an antimicrobial and the design of a rational dosing regimen depends 286 
on the knowledge of the microorganism that causes the disease (clinical experience 287 
or isolation), the action of the drug on the microorganism (pharmacodynamics), the 288 
action of the drug on the animal treated (toxicity) and the availability of the drug for 289 
the animal in question (pharmacokinetics). Other considerations include the 290 
appearance of antimicrobial resistance, animal welfare and the economic cost of the 291 
treatment (Fraile, 2013). In the current work, updated information was obtained about 292 
antimicrobial susceptibility (pharmacodynamic parameter) of ovine respiratory 293 
pathogens under field conditions in Spain and Portugal. Currently, little is known 294 
about antibacterial susceptibility distributions among the target pathogens of sheep 295 
and lambs in EU countries. The current study aims to address this gap by 296 
determining the minimal inhibitory concentrations (MICs) for two major respiratory 297 




and Portugal. One of the critical points is the selection of antimicrobials to be tested. 299 
In this case, we focused on the antibiotics most frequently used through oral (premix 300 
or water) administration for lambs in Spain and Portugal. Thus, sulfadiazine and 301 
trimethoprim (SXT), tetracycline (TET), enrofloxacin (ENR) and doxycycline (DOX) 302 
were chosen following this criteria. From a strictly scientific point of view, it would 303 
have been advisable to include antimicrobials of the macrolide, fenicol and beta-304 
lactamic families to monitor more precisely the antimicrobial susceptibility of these 305 
ovine pathogens but there is a shortage of veterinary medicinal products for use in 306 
lambs with these active ingredients. Thus, information gained would have been of 307 
little practical use. 308 
 309 
The measurement of growth inhibition is carried out by minimum inhibitory 310 
concentration (MIC) determination. The MIC is the lowest antimicrobial concentration 311 
that inhibits in vitro the growth of the target bacteria in specific conditions of 312 
incubation in vitro (usually after 18 to 24 hours in a culture medium at 37ºC and with 313 
a standard amount of inoculums) (Mckellar et al., 2004). In this study, the 314 
antimicrobial susceptibility was determined using artificial culture media as 315 
recommended by international guidelines on antimicrobial susceptibility 316 
determination (CLSI, 2018). This methodology does not emulate the natural biophase 317 
in which bacteria grow in vivo, such as blood, or interstitial and intracellular fluid. This 318 
could lead to a deviation when using the information obtained in vitro to predict the 319 
clinical outcomes in vivo, but the results are more reproducible and comparable 320 
between laboratories and the prediction of clinical efficacy, taking into account this 321 
pharmacodynamic information, is acceptable from a practical point of view (Mckellar 322 




Our samples were collected from diagnostic specimens and we do not have the 324 
whole history of antimicrobial treatments received in those animals before arriving at 325 
the finishing farm. This could have biased the results towards a more resistant 326 
bacterial population that may not be representative for animals that have never 327 
received any antimicrobial therapy. The methods used to test the activity of 328 
antimicrobials against pathogens are mainly agar dilution, broth microdilution, E-test 329 
and diffusion disk (Kelly et al, 1999). Nowadays, broth microdilution is the standard 330 
method for this determination because the diffusion disk technique and E-test were 331 
found to be unreliable for some antimicrobials (e.g., colistin) due to poor diffusion 332 
properties in agar. Nevertheless, other methods may also be used if correctly 333 
validated as in the case of the E-test. This procedure consists of a continuous stable 334 
gradient of antimicrobial agent corresponding to 15 two-fold dilutions on a strip. We 335 
have carried out studies with the E-test to test its agreement with broth microdilution 336 
(BM) for two ovine pathogens and four antimicrobials. Our results indicate that the 337 
agreement is good enough to use in place of BM for our research. The E-test 338 
technique is less labor-intensive and more cost-effective than BM for this particular 339 
case. The good agreement between the E-test and BM was previously demonstrated 340 
for cefditoren with Streptococcus pneumoniae (Kelly et al, 1999) and for telithromycin 341 
with pneumococci (Davies et al, 2000). Nevertheless, it must be studied on a case-342 
by-case basis as a lack of agreement between the E-test and BM was recently 343 
published for colistin and enterobacteriaceae, probably due to its poor diffusion 344 
properties in agar (Turlej-Rogacka et al, 2018). 345 
 346 
Empirical treatment is generally based on knowledge of susceptibility patterns of the 347 




species. However, there is a shortage of information regarding the antimicrobial 349 
susceptibility among disease-causing bacteria from lambs. For the current work, 350 
clinical veterinary breakpoints are not available for lambs. Thus, isolates were not 351 
categorized as susceptible or resistant from a clinical point of view. It is, therefore, 352 
important to present the MIC frequency distributions to allow some interpretation from 353 
a practical point of view (Schwarz et al, 2010). This is feasible because the 354 
susceptible population, referred to as wild type by EUCAST, is also characterized by 355 
the absence of acquired resistance mechanisms and/or mutations leading to 356 
resistance.  357 
 358 
Unfortunately, it is not possible to compare the MIC data in our study with other 359 
studies in lambs because there are no recent studies using similar antimicrobial 360 
agents and guidelines. The information available is very old, was obtained by 361 
obsolete methodology (Diker et al, 1994), comes from a geographical area unrelated 362 
to the European context (Marru et al, 2013) and/or was obtained with pathogens 363 
isolated from mastitis cases (Lollai et al, 2016; Serrano-Rodriguez et al 2017). On the 364 
other hand, the majority of bovine respiratory cases are associated with Pasteurella 365 
multocida (PM) and Mannhaemia haemolytica (MH) infections, which makes 366 
comparisons across species feasible. Our study demonstrates that, taken as a 367 
whole, antimicrobial susceptibility of PM and MH in Spain and Portugal is relatively 368 
high for many licensed antibiotics for ovine respiratory disease, as was previously 369 
published for bovine animals (El Garch et al, 2016). Curiously, the antimicrobial 370 
susceptibility profile is better for PM than for MH not only in ovine but also in bovine 371 
animals (El Garch et al, 2016). On the other hand, the antimicrobial susceptibility is 372 




doxycycline and sulfonamides, the percentage of PM and MH strains with a MIC 374 
value above ECOFF was relatively low (less than 25% in most of the cases) 375 
suggesting that many of them could obtain a positive clinical outcome after treatment 376 
with these antimicrobials. However, the situation is different for tetracycline for which 377 
the former percentage was higher (40% and 53% for PM and MH, respectively) than 378 
that previously described for the rest of the antimicrobials suggesting that the 379 
treatment with this drug could be associated with poor clinical outcomes in many 380 
cases. Finally, the clinical breakpoint described for tetracycline in PM and MH 381 
isolated from bovine (2 g/mL) has the same value for PM (2 g/mL) or is one 382 
dilution lower (4 g/mL) for MH than the tentative ECOFF value described for ovine 383 
animals. On the other hand, the clinical breakpoint described for enrofloxacin in PM 384 
and MH isolated from bovine (0,25 g/mL) is one dilution higher (0.125 g/mL) or a 385 
similar value (0.25 g/mL) than the ECOFF value described for PM and MH in ovine 386 
animals, respectively. Both results suggest that the clinical breakpoints for 387 
tetracycline and enrofloxacin could have the same value as those described for 388 
bovine animals. These data should be validated with accepted methods to establish 389 
clinical breakpoints (Turnidge et al, 2017; Toutain et al, 2017). Unfortunately, a 390 




The results of this study showed an antimicrobial pattern with good susceptibility of 395 
ovine respiratory pathogens to various licensed antibiotics including fluoroquinolones 396 
and sulfonamides. The antimicrobial susceptibility of antibiotics in the tetracycline 397 




tetracycline. Tetracycline should only be used when the susceptibility test has shown 399 
efficacy. Finally, antimicrobial susceptibility monitoring programs of important 400 
veterinary pathogens are necessary to provide evidence-based guidance for 401 
antimicrobial therapy of bacterial diseases. 402 
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Figure captions 602 
 603 
Fig 1. MIC distribution of sulfamethoxazole/trimethoprim for Pasteurella multocida (A) 604 
and Mannhaemia haemolytica (B) isolated from lung or bronchoalveolar lavage of 605 
lambs with respiratory symptoms. Epidemiological breakpoint (ECOFF) is indicated 606 
by a red line. 607 
 608 
Fig 2. MIC distribution of tetracycline for Pasteurella multocida (A) and Mannhaemia 609 
haemolytica (B) isolated from lung or bronchoalveolar lavage of lambs with 610 
respiratory symptoms. Epidemiological breakpoint (ECOFF) is indicated by a red line. 611 
 612 
Fig 3. MIC distribution of enrofloxacin for Pasteurella multocida (A) and Mannhaemia 613 
haemolytica (B) isolated from lung or bronchoalveolar lavage of lambs with 614 
respiratory symptoms. Epidemiological breakpoint (ECOFF) is indicated by a red line. 615 
 616 
Fig 4. MIC distribution of doxycycline for Pasteurella multocida (A) and Mannhaemia 617 
haemolytica (B) isolated from lung or bronchoalveolar lavage of lambs with 618 
respiratory symptoms. Epidemiological breakpoint (ECOFF) is indicated by a red line. 619 
 620 
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 622 
 623 
